Dipeptide-based highly potent doxorubicin antibody conjugates
- 3 November 2005
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (2), 358-362
- https://doi.org/10.1016/j.bmcl.2005.09.081
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- CD70: A NEW TUMOR SPECIFIC BIOMARKER FOR RENAL CELL CARCINOMAJournal of Urology, 2005
- Generation of an Intensely Potent Anthracycline by a Monoclonal Antibody−β-Galactosidase ConjugateBioconjugate Chemistry, 2005
- Design, Synthesis, and in Vitro Evaluation of Dipeptide-Based Antibody Minor Groove Binder ConjugatesJournal of Medicinal Chemistry, 2005
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityBlood, 2003
- Tumor-Specific Novel Taxoid−Monoclonal Antibody ConjugatesJournal of Medicinal Chemistry, 2002
- Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linkerJournal of Controlled Release, 2002
- CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumorsInternational Journal of Cancer, 2002
- Intensely Potent Doxorubicin Analogues: Structure−Activity RelationshipJournal of Medicinal Chemistry, 1998
- N-(5,5-diacetoxypent-1-yl)doxorubicin: a new intensely potent doxorubicin analogJournal of Medicinal Chemistry, 1992
- Intensely potent morpholinyl anthracyclinesJournal of Medicinal Chemistry, 1984